Article
Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
BJU international - 1 Apr 2012
Noon Aidan P, Polański Radosław, El-Fert Ashraf Y, Kalirai Helen, Shawki Howida, Campbell Fiona, Dodson Andy, Eccles Richard M, Lloyd Bryony H, Sibson David R, Coupland Sarah E, Lake Sarah L, Parsons Keith, Vlatković Nikolina, Boyd Mark T
Abstract excerpt
OBJECTIVE: To resolve much debated issues surrounding p53 function, expression and mutation in renal cell carcinoma (RCC), we performed the first study to simultaneously determine p53/MDM2 expression, TP53 mutational status (in p53-positive patients) and outcome in RCC. PATIENTS AND METHODS: In total, 90 specimens obtained from patients with RCC, who were treated by radical nephrectomy, were analyzed by...
Topics
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor
- Carcinoma, Renal Cell
- DNA, Neoplasm
- Disease Progression
- Female
- Gene Expression Regulation, Neoplastic